This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Graaf, A. Articles by Kastelein, J. J.P. Search for Related Content PubMed Articles by van der Graaf, A. Articles by Kastelein, J. J.P. Related Collections Related Article

Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia

Anouk van der Graaf, MD^_*, Cynthia Cuffie-Jackson, MD, Maud N. Vissers, PhD^_*, Mieke D. Trip, MD, PhD, Claude Gagné, MD^||, Genming Shi, PhD, Enrico Veltri, MD, Hans J. Avis, MD^_* and John J.P. Kastelein, MD, PhD^_*,_*

^_* Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Global Clinical Development–Cardiovascular and Metabolic Diseases, Schering-Plough Research Institute, Kenilworth, New Jersey
Biostatistics, Schering-Plough Research Institute, Kenilworth, New Jersey
^|| Lipid Research Center (S-102), CHUL Research Center, Laval University, Quebec, Canada

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Study Design Study design and subject disposition throughout study.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Step 1 (6 Weeks) Reduction in LDL-C From Baseline Changes from baseline in LDL-C in subjects who received coadministered ezetimibe with 10-, 20-, or 40-mg simvastatin (solid bars) or 10-, 20-, or 40-mg simvastatin (open bars) monotherapy after 6 weeks (step 1). *p < 0.01 compared with monotherapy group.